Vanguard Group
CAPR icon

Vanguard Group’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$73.9M Buy
2,561,880
+355,161
+16% +$4.64M ﹤0.01% 1987
2025
Q3 		$15.9M Sell
2,206,719
-98,359
-4% -$724K ﹤0.01% 2737
2025
Q2 		$22.9M Buy
2,305,078
+41,087
+2% +$434K ﹤0.01% 2496
2025
Q1 		$21.5M Sell
2,263,991
-12,793
-0.6% -$178K ﹤0.01% 2476
2024
Q4 		$31.4M Buy
2,276,784
+700,243
+44% +$12.3M ﹤0.01% 2367
2024
Q3 		$24M Buy
1,576,541
+27,600
+2% +$137K ﹤0.01% 2507
2024
Q2 		$7.39M Buy
1,548,941
+183,038
+13% +$1.02M ﹤0.01% 3071
2024
Q1 		$9.27M Buy
1,365,903
+200,499
+17% +$969K ﹤0.01% 3001
2023
Q4 		$5.7M Buy
1,165,404
+13,086
+1% +$42.6K ﹤0.01% 3228
2023
Q3 		$3.94M Buy
1,152,318
+5,600
+0.5% +$31.5K ﹤0.01% 3345
2023
Q2 		$5.48M Sell
1,146,718
-4,625
-0.4% -$20.3K ﹤0.01% 3258
2023
Q1 		$4.86M Sell
1,151,343
-21,500
-2% -$92.6K ﹤0.01% 3315
2022
Q4 		$4.53M Buy
1,172,843
+482
+0% +$2.3K ﹤0.01% 3352
2022
Q3 		$7.03M Buy
1,172,361
+37,500
+3% +$192K ﹤0.01% 3128
2022
Q2 		$3.96M Buy
1,134,861
+113,863
+11% +$404K ﹤0.01% 3500
2022
Q1 		$3.5M Buy
1,020,998
+54,260
+6% +$214K ﹤0.01% 3701
2021
Q4 		$2.83M Sell
966,738
-1,343
-0.1% -$4.71K ﹤0.01% 3903
2021
Q3 		$3.89M Buy
968,081
+44,848
+5% +$204K ﹤0.01% 3804
2021
Q2 		$4.74M Buy
923,233
+11,200
+1% +$47.4K ﹤0.01% 3636
2021
Q1 		$4.27M Buy
912,033
+606,431
+198% +$3.49M ﹤0.01% 3609
2020
Q4 		$1.05M Buy
305,602
+185,490
+154% +$804K ﹤0.01% 3814
2020
Q3 		$631K Buy
120,112
+67,646
+129% +$394K ﹤0.01% 3768
2020
Q2 		$241K Buy
52,466
+23,047
+78% +$100K ﹤0.01% 3901
2020
Q1 		$35K Hold
29,419
– – ﹤0.01% 4023
2019
Q4 		$38K Sell
29,419
-517
-2% -$1.07K ﹤0.01% 4058
2019
Q3 		$111K Sell
29,936
-2
-0% -$7 ﹤0.01% 4028
2019
Q2 		$100K Sell
29,938
-638
-2% -$2.67K ﹤0.01% 4050
2019
Q1 		$142K Hold
30,576
– – ﹤0.01% 3970
2018
Q4 		$125K Sell
30,576
-47,942
-61% -$381K ﹤0.01% 3967
2018
Q3 		$824K Sell
78,518
-281
-0.4% -$3.35K ﹤0.01% 3763
2018
Q2 		$1.06M Buy
78,799
+7,546
+11% +$103K ﹤0.01% 3671
2018
Q1 		$969K Sell
71,253
-123
-0.2% -$2.13K ﹤0.01% 3653
2017
Q4 		$1.13M Buy
71,376
+27,142
+61% +$587K ﹤0.01% 3588
2017
Q3 		$1.34M Buy
44,234
+35,852
+428% +$429K ﹤0.01% 3514
2017
Q2 		$70K Buy
8,382
+1,749
+26% +$32K ﹤0.01% 4006
2017
Q1 		$221K Buy
6,633
+1,554
+31% +$43.1K ﹤0.01% 3891
2016
Q4 		$135K Buy
5,079
+2,181
+75% +$65.3K ﹤0.01% 3946
2016
Q3 		$96K Buy
2,898
+100
+4% +$3.76K ﹤0.01% 3983
2016
Q2 		$111K Buy
2,798
+571
+26% +$20.2K ﹤0.01% 4016
2016
Q1 		$56K Hold
2,227
– – ﹤0.01% 4069
2015
Q4 		$69K Buy
2,227
+710
+47% +$28.2K ﹤0.01% 4115
2015
Q3 		$61K Buy
1,517
+297
+24% +$13.2K ﹤0.01% 4130
2015
Q2 		$62K Buy
+1,220
New +$76.6K ﹤0.01% 4144

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Vanguard Group's CAPR Position: Q4 2025 in Review

Vanguard Group increased its Capricor Therapeutics (CAPR) stake by 16% in Q4 2025, buying an estimated $4.64M and bringing the position to 2,561,880 shares worth $73.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1987.

Vanguard Group first reported a position in CAPR in Q2 2015 and has held it in 43 quarters since. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Vanguard Group held 2,561,880 shares of Capricor Therapeutics worth $73.9M as of Q4 2025.
  • Vanguard Group bought 355,161 Capricor Therapeutics shares in Q4 2025, an estimated $4.64M.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1987 holding.
  • Vanguard Group first reported a position in Capricor Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.